Literature DB >> 8605937

Expression of bcl-x during mouse B cell differentiation and following activation by various stimuli.

M S Choi1, M Holmann, C J Atkins, G G Klaus.   

Abstract

We have studied the expression of the novel anti-apoptotic protein bcl-x during mouse B cell differentiation and activation. We find that bcl-x is expressed throughout all stages of B cell differentiation in the bone marrow, and is only down-regulated in mature (sIgD+) B cells. Immature peripheral B cells express low levels of bcl-x even in adult animals, whereas mature resting B cells do not. Mature B cells re-express the protein following activation, achieving maximal levels after 36-48 h. The highest levels of bcl-x are observed with potent mitogenic stimuli (such as anti-CD40 + anti-Ig): B cells first express bcl-x in the G1 phase of the cell cycle and contain maximal levels in S phase. In addition, B cells from CBA/N mice, which do not proliferate when stimulated with anti-Ig, anti-CD40 or both, exhibited only low levels of the protein following culture with these stimuli. To investigate the functional significance of bcl-x in activated B cells, we tested their sensitivity to apoptosis induced by the Ca2+ ATPase inhibitor thapsigargin: B cell blasts activated with anti-CD40 and anti-Ig were resistant to this agent. The available data therefore suggest that bcl-x fulfils two roles in B cells: it promotes survival of immature B cells (which lack bcl-2) and secondly, it apparently plays an additional role in protecting activated mature B cells (perhaps those in germinal centers) from apoptotic stimuli.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605937     DOI: 10.1002/eji.1830260325

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  An essential role for Bruton's [corrected] tyrosine kinase in the regulation of B-cell apoptosis.

Authors:  J S Anderson; M Teutsch; Z Dong; H H Wortis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 2.  The role of germinal centers for antiviral B cell responses.

Authors:  M F Bachmann
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 3.  Bcl-x and the regulation of survival in the immune system.

Authors:  T W Behrens; D L Mueller
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

4.  Rewiring of CD40 is necessary for delivery of rescue signals to B cells in germinal centres and subsequent entry into the memory pool.

Authors:  K Siepmann; J Skok; D van Essen; M Harnett; D Gray
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

5.  Activation sensitizes human memory B cells to B-cell receptor-induced apoptosis.

Authors:  M Berard; M Casamayor-Pallejà; G Billian; C Bella; P Mondière; T Defrance
Journal:  Immunology       Date:  1999-09       Impact factor: 7.397

6.  Relaxed negative selection in germinal centers and impaired affinity maturation in bcl-xL transgenic mice.

Authors:  Y Takahashi; D M Cerasoli; J M Dal Porto; M Shimoda; R Freund; W Fang; D G Telander; E N Malvey; D L Mueller; T W Behrens; G Kelsoe
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

7.  Transgene expression of bcl-xL permits anti-immunoglobulin (Ig)-induced proliferation in xid B cells.

Authors:  N Solvason; W W Wu; N Kabra; F Lund-Johansen; M G Roncarolo; T W Behrens; D A Grillot; G Nunez; E Lees; M Howard
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

8.  Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.

Authors:  J B Petro; S M Rahman; D W Ballard; W N Khan
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

9.  Activated Ras signals developmental progression of recombinase-activating gene (RAG)-deficient pro-B lymphocytes.

Authors:  A C Shaw; W Swat; R Ferrini; L Davidson; F W Alt
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.